Nareg Sagherian | Executive Director, Global IR |
Jerome Durso | President, CEO & Director |
Linda Richardson | EVP & Chief Commercial Officer |
Michelle Berrey | President, Research & Development and Chief Medical Officer |
Andrew Saik | CFO |
Yasmeen Rahimi | Piper Sandler & Co. |
Ritu Baral | Cowen |
Steven Seedhouse | Raymond James & Associates |
Michael Yee | Jefferies |
Antonio Arce | H.C. Wainwright & Co. |
Mayank Mamtani | B. Riley Securities |
Thomas Smith | SVB Securities |
Eliana Merle | UBS |
Luke Herrmann | Robert W. Baird & Co. |
Catherine Okoukoni | JMP Securities |
Good day, and thank you for standing by. Welcome to the Q3 2022 Intercept Pharmaceuticals Earnings Call. [Operator Instructions].
I would now like to hand the conference over to your speaker today, Nareg Sagherian, Executive Director, Investor Relations. Please go ahead.